IP Library › Patent Application 13158082
Patent Application
App. No. 13/158,082

Methods of Quantifying Methotrexate Metabolites

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/158,082
Abstract

The present invention provides a method for efficiently converting methotrexate polyglutamates to methotrexate in a cellular extract by contacting the cellular extract with gamma glutamyl hydrolase under conditions suitable for efficient conversion of methotrexate polyglutamates to methotrexate.

Claims (1)

1 . A method for predicting therapeutic efficacy or reducing toxicity associated with methotrexate (MTX) therapy administered to an individual, comprising the steps of: (a) converting methotrexate polyglutamates (MTXPGs) to MTX in a cellular extract from said individual under conditions suitable for efficient conversion of MTXPGs to MTX; (b) determining a level of MTX in said cellular extract, said level of MTX correlating with a level of MTXPGs, thereby determining a level of MTXPGs in said cellular extract, wherein a drug or dosage subsequently administered to said individual is selected based on said level of MTXPGs.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2021
From: PROMETHEUS BIOSCIENCES, INC.
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 057730/0993 →
CHANGE OF NAME Recorded Oct 17, 2019
From: PRECISION IBD, INC.
To: PROMETHEUS BIOSCIENCES, INC.
Reel/Frame 050886/0942 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2019
From: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
To: PRECISION IBD, INC.
Reel/Frame 050166/0001 →